Q32 Bio Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2026, with the U.S. Securities and Exchange Commission, disclosing its financial condition, risk factors, and operational status as a clinical-stage biopharmaceutical company.

Key Highlights

  • Share count: As of August 3, 2026, the company had 29,769,466 shares of common stock, $0.0001 par value per share, outstanding.
  • No product revenue: According to the filing, the company "has no products for sale, have not generated any product revenue and may never generate product revenue or become profitable."
  • Lead candidate: The filing identifies bempikibart as the company's most advanced product candidate, noting the company is "substantially dependent on the success" of that program.
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
  • Capital needs: The filing states the company "will require substantial additional capital to finance our operations in the future."
  • Listing risk: The filing identifies a risk that failure to meet continued listing requirements of the Nasdaq Capital Market "could result in a delisting of our securities."

Q32 Bio's Quarterly Disclosure: Pipeline Status and Key Risks

Q32 Bio Inc. (Nasdaq Capital Market: QTTB), headquartered at 830 Winter Street, Waltham, MA 02451, filed its Form 10-Q for the quarterly period ended June 30, 2026. The company is incorporated in Delaware and carries IRS Employer Identification Number 47-3468154. The filing covers the company's operations as a clinical-stage biopharmaceutical company with no approved products and no product revenue to date.

According to the filing, the company has "incurred significant operating losses since inception" and "expects to incur significant losses for the foreseeable future." The disclosure states that additional financing will be required, and that if capital cannot be raised "when needed, or on acceptable terms," the company "may be forced to delay, reduce or eliminate clinical trials, product development programs or future commercialization efforts." The company's primary pipeline asset, bempikibart, is described as being in early stages of development.

The filing notes that the company relies on third parties for the supply and manufacture of its product candidates. It also cites risks related to intellectual property protection, competition, key personnel retention, and macroeconomic conditions. The filing includes forward-looking statements, which the company cautions are subject to risks and uncertainties, and are identified by words such as "anticipate," "believe," "estimate," "expect," and similar expressions, among others listed in the filing.

What Was Disclosed

Q32 Bio filed its Q2 2026 quarterly report disclosing its clinical-stage status with no product revenue, continued operating losses, reliance on bempikibart as its lead candidate, and a need for additional capital to sustain operations.